X-0002 is under clinical development by Techfields Pharma and currently in Phase III for Osteoarthritis Pain. According to GlobalData, Phase III drugs for Osteoarthritis Pain have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how X-0002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

X-0002 overview

X-0002 (Ibuprofenamine) is under development for the treatment of osteoarthritis pain of knee, degenerative (neck and back) disease, prostatitis and fever. It is a small molecule. The drug candidate is administered by transdermal route. It is a non-steroidal anti-inflammatory drug (NSAID) which acts by targeting COX enzymes, COX-1 and COX-2. It is based on transdermal drug delivery technology.

It was under development for pain of the lumbar spine, acute pain, gouty arthritis, rheumatoid arthritis (RA) and edema.

For a complete picture of X-0002’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.